Belumosudil, sold under the brand name Rezurock among others, is a medication used for the treatment of chronic graft versus host disease (cGvHD).

[12] In October 2017, belumosudil was granted orphan drug status in the United States for treatment of people with chronic graft-versus-host disease.

[9] On 16 July 2021, the US Food and Drug Administration (FDA) approved belumosudil for people aged twelve years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.

[6][10] Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic disease where the lining of the lungs become thickened and scarred.

Down-regulation of pro-inflammatory responses was observed with KD025 (belumosudil) treatment in Phase 2 clinical studies in patients with moderate to severe psoriasis.